Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Maakamil who wrote (10249)	11/12/1998 10:06:00 AM
From: Yoav Chudnoff	Respond to of 119973

Hope some of you bought some ALLP during this morning's downturn, looking bright and cheery

To: Maakamil who wrote (10249)	11/12/1998 10:07:00 AM
From: Bradpalm1	Read Replies (1) \| Respond to of 119973

Oxygent works in Phase II trials, the real question is how many hoops the FDA will make it jump through to accept the results from the Phase III trials. No better blood substitute candidate out there at this time. If it hits it hits BIG! Bradpalm1

To: Maakamil who wrote (10249)	11/12/1998 10:14:00 AM
From: Lane Hall-Witt	Read Replies (3) \| Respond to of 119973

Funny thing is, for a R&D biotech firm like ALLP, increased losses can actually be a good sign since it indicates that they're ramping up for testing. ALLP holds more than 50 patents (most recent one issued Nov. 3), has one product already in Phase III, and has two more products about to enter Phase III. (Getting Phase III approval is extremely rare: according to the ALLP Web site, only 1 of 1,000 compounds that enter preclinical testing even make it to Phase I.) More than one-third of the company's shares are held by institutions. A few references for DD: allp.com uspto.gov fda.gov marketguide.com I think the early selling came from yesterday's short-term traders and from those spooked by ENMD.